Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H13Cl2N3.BrH |
| Molecular Weight | 351.07 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.ClC1=CC=CC(Cl)=C1N(CC=C)C2=NCCN2
InChI
InChIKey=JLFOQBZGELKSOT-UHFFFAOYSA-N
InChI=1S/C12H13Cl2N3.BrH/c1-2-8-17(12-15-6-7-16-12)11-9(13)4-3-5-10(11)14;/h2-5H,1,6-8H2,(H,15,16);1H
| Molecular Formula | C12H13Cl2N3 |
| Molecular Weight | 270.158 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Alinidine, a specific bradycardiac agent, which reduces myocardial oxygen consumption and improves exercise tolerance in patients with angina pectoris. In randomized controlled trial alinidine did not enhance myocardial salvage or preservation of left ventricular function of major arrhythmias in the early phase of infarction. The development of this drug was stopped because it was not sufficiently specific for its target.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacological stimulation and inhibition of insulin secretion in mouse islets lacking ATP-sensitive K+ channels. | 2010-02-01 |
|
| Selective enhancement of nutrient-induced insulin secretion by ATP-sensitive K+ channel-blocking imidazolines. | 2009-12 |
|
| Heart rate and cardiovascular disease: an alternative to Beta blockers. | 2009 |
|
| Antagonism of the insulinotropic action of first generation imidazolines by openers of K(ATP) channels. | 2007-01-01 |
|
| Molecular regulation and pharmacology of pacemaker channels. | 2007 |
|
| [Selective I(f) channel inhibition: an alternative for treating coronary artery disease?]. | 2006-02 |
|
| Physiology and pharmacology of the cardiac pacemaker ("funny") current. | 2005-07 |
|
| Reduction of heart rate by chronic beta1-adrenoceptor blockade promotes growth of arterioles and preserves coronary perfusion reserve in postinfarcted heart. | 2005-06 |
|
| Angiogenesis in ischaemic and hypertrophic hearts induced by long-term bradycardia. | 2005 |
|
| Bradycardia induces angiogenesis, increases coronary reserve, and preserves function of the postinfarcted heart. | 2004-08-17 |
|
| Specificity of nonadrenergic imidazoline binding sites in insulin-secreting cells and relation to the block of ATP-sensitive K(+) channels. | 2003-12 |
|
| Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven? | 2003-06 |
|
| Desensitization of insulin secretory response to imidazolines, tolbutamide, and quinine. II. Electrophysiological and fluorimetric studies. | 2001-12-15 |
|
| Desensitization of insulin secretory response to imidazolines, tolbutamide, and quinine. I. Secretory and morphological studies. | 2001-12-15 |
|
| Control of catecholamine-induced tachycardia with alinidine in the anesthetized dog. | 1987-08 |
|
| Alinidine in angina. | 1983-12 |
|
| Effect of alinidine on experimental cardiac arrhythmias. | 1982-03-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8335810
alinidine (20 to 40 mg intravenously followed by 20 to 40 mg orally every 8 h)
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:00:29 GMT 2025
by
admin
on
Mon Mar 31 23:00:29 GMT 2025
|
| Record UNII |
Q8XXC72UBI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Q8XXC72UBI
Created by
admin on Mon Mar 31 23:00:29 GMT 2025 , Edited by admin on Mon Mar 31 23:00:29 GMT 2025
|
PRIMARY | |||
|
71306-36-0
Created by
admin on Mon Mar 31 23:00:29 GMT 2025 , Edited by admin on Mon Mar 31 23:00:29 GMT 2025
|
PRIMARY | |||
|
134052
Created by
admin on Mon Mar 31 23:00:29 GMT 2025 , Edited by admin on Mon Mar 31 23:00:29 GMT 2025
|
PRIMARY | |||
|
DTXSID10221461
Created by
admin on Mon Mar 31 23:00:29 GMT 2025 , Edited by admin on Mon Mar 31 23:00:29 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |